Evaluating no evidence of disease activity in patients with relapsing multiple sclerosis: post hoc analysis of the Phase 3 RADIANCE and open-label Extension Studies …
Objective: To assess no evidence of disease activity 3 and 4 (NEDA-3 and NEDA-4) in
patients with RMS treated with ozanimod. Background: NEDA is a composite efficacy …
patients with RMS treated with ozanimod. Background: NEDA is a composite efficacy …
De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who …
M Gudesblatt, B Bumstead, M Buhse, M Zarif… - Advances in …, 2024 - Springer
Introduction Switching disease-modifying therapy (DMT) may be considered for relapsing–
remitting multiple sclerosis (RRMS) if a patient's current therapy is no longer optimal. This …
remitting multiple sclerosis (RRMS) if a patient's current therapy is no longer optimal. This …
[PDF][PDF] Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis
D Stokmaier, K Winthrop, C Chognot, J Evershed… - …, 2018 - ocrelizumabinfo.global
BACKGROUND• Ocrelizumab (OCR) is a high-efficacy treatment approved for relapsing
multiple sclerosis (RMS) 1 and is the first approved treatment for primary progressive …
multiple sclerosis (RMS) 1 and is the first approved treatment for primary progressive …
Exploratory MRI biomarkers of opicinumab (anti-LINGO-1) show stabilization of pre-existing T2 lesions in relapsing multiple sclerosis: results from the phase 2b …
KC Evans, R Naismith, DL Arnold, A Boyko… - Neurology, 2017 - AAN Enterprises
Objective: To determine the effect of treatment on MRI measures/clinical response in
SYNERGY. Background: SYNERGY (NCT01864148) evaluated opicinumab (BIIB033) vs …
SYNERGY. Background: SYNERGY (NCT01864148) evaluated opicinumab (BIIB033) vs …
Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis
Abstract Introduction Ocrelizumab (OCR) and Fingolimod (FGL) are two high-efficacy
treatments in multiple sclerosis which, besides their strong anti-inflammatory activity, may …
treatments in multiple sclerosis which, besides their strong anti-inflammatory activity, may …
[PDF][PDF] B Cells, T Cells and inflammatory CSF biomarkers in primary progressive MS and relapsing MS in the OBOE (ocrelizumab biomarker outcome evaluation) trial
AH Cross has, in the past year, received fees or honoraria for consulting from Biogen,
Celgene, EMD Serono, F. Hoffmann-La Roche Ltd, Genentech, Inc. and Novartis and …
Celgene, EMD Serono, F. Hoffmann-La Roche Ltd, Genentech, Inc. and Novartis and …
[PDF][PDF] Eight-Year Analyses of Repeated Confirmed Disability Progressions in the OPERA I/II and ORATORIO Studies and Their Open-Label Extensions
L Kappos, HSL HartungHEp - 2022 - cuba.dialogoroche.com
Background aSee also slides 4 and 5. IFN, interferon; MS, multiple sclerosis; OCR,
ocrelizumab; OLE, open-label extension; PBO, placebo; PPMS, primary progressive multiple …
ocrelizumab; OLE, open-label extension; PBO, placebo; PPMS, primary progressive multiple …
Histologic manifestations of ocrelizumab‐associated intestinal and hepatic injury in patients with multiple sclerosis
B Challa, AK Esnakula - Histopathology, 2024 - Wiley Online Library
Aims Ocrelizumab is a humanized anti‐CD20‐monoclonal antibody that has recently been
approved for the treatment of certain types of multiple sclerosis. Isolated case reports of …
approved for the treatment of certain types of multiple sclerosis. Isolated case reports of …
Ocrelizumab excites ECTRIMS
I Fyfe - Nature Reviews Neurology, 2015 - nature.com
Ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, looks set to
transform treatment of both relapsing–remitting and progressive multiple sclerosis (MS) …
transform treatment of both relapsing–remitting and progressive multiple sclerosis (MS) …